Pharmacokinetics of Amiodarone in hyperlipidemic and simulated high fat‐meal rat models
暂无分享,去创建一个
D. Brocks | A. Shayeganpour | A. S. Jun | Dion R Brocks | Anooshirvan Shayeganpour | Andrew S Jun | Dion R. Brocks
[1] T. Johnston,et al. Biological activity of urease formulated in poloxamer 407 after intraperitoneal injection in the rat. , 1992, Journal of pharmaceutical sciences.
[2] S. Nattel,et al. Comparative electrophysiologic effects of intravenous amiodarone and desethylamiodarone in dogs: evidence for clinically relevant activity of the metabolite. , 1987, Circulation.
[3] E. Riva,et al. Pharmacokinetics of Amiodarone in Rats , 1982, Journal of cardiovascular pharmacology.
[4] K. Williams,et al. Therapeutic drug monitoring: antiarrhythmic drugs. , 1998, British journal of clinical pharmacology.
[5] G. Edwards,et al. Association of halofantrine with postprandially derived plasma lipoproteins decreases its clearance relative to administration in the fasted state. , 1998, Journal of pharmaceutical sciences.
[6] T. Bouillon,et al. Population pharmacokinetics of long‐term oral amiodarone therapy , 2000, Clinical pharmacology and therapeutics.
[7] D. Brocks,et al. The influence of lipids on stereoselective pharmacokinetics of halofantrine: Important implications in food-effect studies involving drugs that bind to lipoproteins. , 2002, Journal of pharmaceutical sciences.
[8] C. Klaassen,et al. Mechanisms of bile formation, hepatic uptake, and biliary excretion. , 1984, Pharmacological reviews.
[9] M. Lalloz,et al. Binding of amiodarone by serum proteins and the effects of drugs, hormones and other interacting ligands , 1984, The Journal of pharmacy and pharmacology.
[10] P. Wyss,et al. Single-dose kinetics of tissue distribution, excretion and metabolism of amiodarone in rats. , 1990, The Journal of pharmacology and experimental therapeutics.
[11] G. Hollander,et al. Giving IV and oral amiodarone perioperatively for the prevention of postoperative atrial fibrillation in patients undergoing coronary artery bypass surgery: the GAP study. , 2004, Chest.
[12] Y. Yim,et al. Characterization of amiodarone metabolites and impurities using liquid chromatography/atmospheric pressure chemical ionization mass spectrometry. , 2000, Rapid communications in mass spectrometry : RCM.
[13] Douglas L Packer,et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. , 2005, The New England journal of medicine.
[14] T. Johnston. The P-407–Induced Murine Model of Dose-Controlled Hyperlipidemia and Atherosclerosis: A Review of Findings To Date , 2004, Journal of cardiovascular pharmacology.
[15] R. McPherson,et al. Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: summary of the 2003 update. , 2003, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.
[16] A. Auricchio,et al. New primary prevention trials of sudden cardiac death in patients with left ventricular dysfunction: SCD-HEFT and MADIT-II. , 1999, The American journal of cardiology.
[17] T. Johnston,et al. Mechanism of poloxamer 407-induced hypertriglyceridemia in the rat. , 1993, Biochemical pharmacology.
[18] J. Kharidia,et al. Effects of desethylamiodarone on the electrocardiogram in conscious freely moving animals: pharmacokinetic and pharmacodynamic modeling using computer-assisted radio telemetry. , 1996, Biopharmaceutics & drug disposition.
[19] J. Mason. Drug therapy: amiodarone , 1987 .
[20] P. Tso,et al. Effect of fat pre-feeding on bile flow and composition in the rat. , 1991, Biochimica et biophysica acta.
[21] G. Naccarelli,et al. Amiodarone: What have we learned from clinical trials? , 2000, Clinical cardiology.
[22] Tim Morris,et al. Physiological Parameters in Laboratory Animals and Humans , 1993, Pharmaceutical Research.
[23] J. Heubi,et al. Adaptive response of the enterohepatic circulation of bile acids to extrahepatic cholestasis , 1996, Hepatology.
[24] P. Bjerregaard,et al. Pharmacokinetics of amiodarone after intravenous and oral administration , 1981, European Journal of Clinical Pharmacology.
[25] J. Schuhmacher,et al. Determination of the free fraction and relative free fraction of drugs strongly bound to plasma proteins. , 2000, Journal of pharmaceutical sciences.
[26] G. Tognoni,et al. Clinical Pharmacokinetics of Amiodarone , 1984, Clinical pharmacokinetics.
[27] G. Naccarelli,et al. Amiodarone: clinical trials. , 2000, Current opinion in cardiology.
[28] I Weinryb,et al. Bioavailability of amiodarone tablets administered with and without food in healthy subjects. , 2001, The American journal of cardiology.